EyePoint Pharmaceuticals Inc. (EYPT)
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
EyePoint (EYPT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.64 per share a year ago.
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know
Does EyePoint (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. ( EYPT ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants George Elston - Executive VP & CFO Jay Duker - President, CEO & Director Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good morning. My name is Antoine, and I will be your conference operator today.
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.54 per share a year ago.
EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Citi's Biopharma Back to School Conference September 2, 2025 2:30 PM EDT Company Participants Jay Duker - President, CEO & Director George Elston - Executive VP & CFO Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst [Audio Gap] With EyePoint. [Operator Instructions] and welcome as well to those listening on the webcast.
EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants George O. Elston - Executive VP & CFO Jay S.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $0.58 per share a year ago.
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent dosing could offer a key advantage over current market leaders Eylea and Vabysmo. Rapid enrollment in Phase 3 trials and robust safety/efficacy data boost confidence, but competition and market fragmentation remain significant risks.
